Summit Therapeutics (SMMT) Liabilities and Shareholders Equity (2019 - 2026)

Summit Therapeutics (SMMT) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $752.2 million the latest figure, recorded in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 132.13% year-over-year to $752.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.4 billion (up 46.57% YoY) and the FY2025 annual result came in at $751.2 million, up 72.46% from the prior year.
• Liabilities and Shareholders Equity rose to $752.2 million in Q2 2026 per SMMT's latest filing, from $647.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for SMMT reached as high as $752.2 million in Q2 2026 and fell as low as $95.7 million in Q2 2022.
• A 5-year average of $362.4 million and a median of $292.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 485.82% — and 2023, when it sank 69.44%.
• Year by year, Liabilities and Shareholders Equity stood at $664.2 million in 2022, then plunged by 69.44% to $202.9 million in 2023, then soared by 114.62% to $435.6 million in 2024, then surged by 72.46% to $751.2 million in 2025, then increased by 0.13% to $752.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $752.2 million, $647.9 million, and $751.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.